A prospective Kenyan cohort study identifies that post-tuberculosis lung disease (PTLD) affects 50% of survivors, driven by divergent transcriptomic signatures: early pro-fibrotic inflammation in restrictive phenotypes and persistent interferon signaling in obstructive phenotypes.